Lactobacillus rhamnosus BMX 54 + Lactose, A Symbiotic Long-Lasting Vaginal Approach to Improve Women’s Health
Open accessAbstract
Abstract: The proposal to restore vaginal microbiota using biotherapeutic agents ended with controversial results. Vaginal microbiota modifications from eubiosis to dysbiosis (desquamative inflammatory vaginitis, “aerobic vaginitis”) and pathobiosis have recently been demonstrated to have a pivotal role in women’s clinical health. Bacterial vaginosis (BV) and its related women’s pathology seem to be “the most common vaginal infections” in women; the Center for Disease Control (CDC) recommended treatment for this pathology: metronidazole, clyndamicin or other well known treatment such as dequalinium chloride, unfortunately, has been demonstrated to fail in control of this infection and especially in its recurrence rates. A long-lasting vaginal approach with a symbiotic drug ( Lactobacillus rhamnosus BMX 54 + lactose) (NORMOGIN™) has demonstrated on a large sample of women enrolled in clinical trials (more than 3000 patients) not only to be able to significantly reduce the BV recurrences, after the CDC standard of care administration, but also to control the vaginal pathobiosis pathway, restoring the physiological eubiosis from dysbiosis. These results are really very encouraging and clearly demonstrate that a symbiotic long-lasting vaginal application of a selected Lactobacillus population plus a prebiotic could be helpful if added to the recommended standard of care. Keywords: bacterial vaginosis, Lactobacillus rhamnosus BMX 54 , pathobiosis pathway
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Following the Friedrich three-step model, a specific protocol has been used and validated in more than 3000 women affected by vaginitis.
“During the last 20 years, several clinical trials have been published using this approach [47-65]: following the Friedrich three-step model ( Figure 2 ), a specific protocol has been used and validated in more than 3000 women affected by vaginitis [42].”
From Vaginal microbiota and urinary tract infections in women: the protective role of vaginal lactobacilli in counteracting urinary tract infections occurrence and recurrence (2026) · cites this paper as [42]
The Abstract (page not provided) describes a long-lasting vaginal treatment approach and reports clinical trials involving more than 3,000 patients. It does not identify that approach as following Friedrich’s three-step model or establish that all 3,000 patients were affected by vaginitis. (LLM, conf=0.84)
Experimental — accuracy not yet measuredAfter using a specific antibiotic treatment against the causative agent, the vaginal application of a symbiotic drug (vaginal tabs containing Lactobacillus rhamnosus BMX 54 as the active principle plus lactose as the selected prebiotic), according to the protocol, has been clinically validated and used with statistically significant effectiveness in counteracting vaginitis recurrences.
“After using a specific antibiotic treatment against the causative agent, the vaginal application of a symbiotic drug (vaginal tabs containing Lactobacillus rhamnosus BMX 54 as the active principle plus lactose as the selected prebiotic), according to the following protocol, has been clinically validated and used with statistically significant effectiveness in counteracting vaginitis recurrences (”
From Vaginal microbiota and urinary tract infections in women: the protective role of vaginal lactobacilli in counteracting urinary tract infections occurrence and recurrence (2026) · cites this paper as [42]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 21
- [1]Wiesenfeld HC, Hiller SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol. 2002; 100: 453– 456. 12220764
- [2]Ness RB, Kip KE, Hiller SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005; 162: 585– 590. doi: 10.1093/aje/kwi243 16093289 · DOI
- [3]Spear GT, Glibert D, Landay AL, et al. Pyrosequencing of the genital microbiotas of HIV-sieronegative women reveals Lactobacillus iners as the predominant Lactobacillus species. Appl Environ Microbiol. 2011; 77: 378– 381. doi: 10.1128/AEM.00973-10 21075899 PMC3019699 · DOI
- [4]Bertini M. Bacterial vaginosis and sexually transmitted diseases: relationship and management In: Serdaroglu S, Kutlubay Z, editors. Fundamentals of Sexually Transmitted Infections. INTECH Open; 2017: 75.
- [5]Palma E, Bertini M. Vaginal microbiota and the pathobiosis path: its role in the evolution of the HPV cervical intraephitelial neoplasia and cancer. Eur J Gynaecol Oncol. 2019; 40(4): 534– 537.
- [6]Albert DM, Doderlein G. A critical view to the bibliographies of two German Professor. Zentralbl Gynakol. 2006; 128(2): 56– 59. 16673245
- [7]Miller EA, Beasley DE, Dunn RR, Archie EA. Lactobacilli dominance and vaginal pH: why is the human vaginal microbiome unique? Front Microbiol. 2016; 7: 1936. 28008325 PMC5143676
- [8]GaGhazzewiFH A, Teser RF. Biotherapeutic agents and vaginal health. J Appl Microbiol. 2016; 121(1): 18– 27. doi: 10.1111/jam.13054 26757173 · DOI
- [9]Balkus JE, Jakho W, Temmerman M, et al. The post-trial effect of oral periodic presuntive treatment for vginal infection on the incidence of bacterial vaginosis and Lactobacillus colonization. Sex Transm Infect. 2012; 29: 361– 365. PMC3335440 22504600
- [10]Serok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev. 2009;(4): CD006289. 19821358
- [11]Lev-Sagie A, Glodman-Wohl D, Cohen Y. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat Med. 2019; 25: 1500– 1504. doi: 10.1038/s41591-019-0600-6 31591599 · DOI
- [12]Parma M, Stella Vanni V, Bertini M, Candiani M. Probiotics in the prevention of recurrences of bacterial vaginosis. Altern Ther Health Med. 2014; 20: 52– 57. 24473986
- [13]Recine N, Musciola A, Moreira E. The benefits of topical vaginal therapy with Lactobacillus casei sub-rhamnosus in preventing bacterial vaginosis relapses. In: Abstract Book of the X National IBAT Conference Naples; 1 26 – 28, 2018.
- [14]Rossi A, Rossi T, Bertini M. The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months. Arch Gynecol Obstet. 2010; 281: 1065– 1069. doi: 10.1007/s00404-009-1287-6 20012637 · DOI · Paper page
- [15]Bertini M. Is Lactobacillus rhamnosus BMX 54 vaginal application a strategy to counteract bacterial vaginosis recurrences?: Proceedings of 18th World Congress on Controversis in Obstetrics, Gynecology and Infertility (COGI), Wien 10 24 – 27, 2013
- [16]Recine N, Palma E, Domenici L, et al. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Arch Gynecol Obstet. 2016; 23(1): 101– 107. doi: 10.1007/s00404-015-3810-2 26142892 · DOI · Paper page
- [17]Marcone V, Rocca B, Lichtner M, Calzolari E. Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis. Int J Obstet Gynecol. 2010; 110: 223– 226. doi: 10.1016/j.ijgo.2010.04.025 20573348 · DOI
- [18]Stojanovic N, Plecas D, Plesinac S. Normal vaginal flora disorders and application of probiotics in pregnancy. Arch Gynecol Obstet. 2012; 286(2): 325– 332. doi: 10.1007/s00404-012-2293-7 22437191 · DOI
- [19]Recine N, Palma E, Domenici L, Giorgini M, Pierangeli A, Benedetti Panici P Long-term probiotic implementation to re-create a balanced vaginal ecosystem: a promising boost against HPV. In: Abstract Book of International Scientific Conference on Probiotics and Prebiotics; 6 21 – 23, 2016; Budapest Hungary.
- [20]Luzi G, Iazzetta E, Cecconi L, et al. Lactobacillus rhamnosus BMX 54 vaginal application usefulness as adjuvant therapy for preterm premature rupture of membranes (PPROM) in the second trimester of pregnancy. Int J Pediatr Neonatal Health. 2018; 2(1): 14– 18.
- [21]Palma E, Recine N, Domenici L, Giorgini M, Pierangeli A, Panici PGB. Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV infection. BMC Infect Dis. 2018; 18(1): 1– 7. 29304768 PMC5756375
Cited by
Sorted by citations
- Authors
- Baldacci, F., Baldacci, M., & Bertini, M.
- Affiliations
- Baldacci (Italy) (IT)
- Corresponding author
- Baldacci, Filippo
- Baldacci, Mara
- Bertini, Marco
- ORCID
- Bertini, Marco
- Venue
- International Journal of Women's Health
- Publisher
- Informa UK Limited
- Published
- 2020-11
- Volume
- Volume 12
- Pages
- 1099-1104
- ISSN
- 1179-1411 (ISSN-L)
- PMC
- PMC7684798
- OpenAlex
- W3098052648
- Cited by
- 10
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 3 · 2022: 1
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Women s Health (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- lactose, probiotics, bacterial vaginosis, vaginal microbiota, vaginal dysbiosis, prebiotics, women's health, vaginal infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
